Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-03-24 14:00 CET (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company’s commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.
In recognition of World TB Day, Oxford Immunotec will be actively supporting and participating in many important symposia and events focused on the prevention and management of TB, including the Annual Tuberculosis Symposium at the London School of Hygiene and Tropical Medicine's TB Centre, the HIV Diagnostics Conference in Atlanta, Georgia and the World TB Symposium at Rutgers New Jersey Medical School. Further, Oxford Immunotec will host a special presentation by renowned TB expert Elizabeth Talbot, MD, Associate Professor of Medicine at Geisel School of Medicine, Dartmouth College, Hanover, NH, at its US headquarters in Marlborough, Massachusetts, Dr. Talbot will present “Advances in TB: A Year in Review”.
“A critical step in the effort to eliminate TB is building broader awareness among healthcare providers of the risk factors and the need for continued vigilance along with targeted, efficient and effective TB screening and screening follow up,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Our commitment to education regarding the continued global threat posed by TB and the benefits of screening programs using the T-SPOT®.TBtest aim to expand understanding that TB is a preventable disease and that TB testing programs save thousands of lives each year.”
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMVtest and the T-SPOT.PRTtest are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and theOxford Immunoteclogo are trademarks ofOxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0500
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Crown Bioscience Inc.23.11.2017 14:01 | pressemeddelelse
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring
Bermuda Business Development Agency (BDA)23.11.2017 06:26 | pressemeddelelse
BDA partners with government to attract cryptocurrency
VistaJet Ltd22.11.2017 11:40 | pressemeddelelse
VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller
Nasdaq22.11.2017 10:03 | pressemeddelelse
Nasdaq to Deliver Blockchain e-Voting Solution to Strate
Oxford Immunotec21.11.2017 15:16 | pressemeddelelse
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
Crown Bioscience Inc.21.11.2017 14:02 | pressemeddelelse
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum